Salud financiera de hoja de balance de Sage Therapeutics
Salud financiera controles de criterios 5/6
Sage Therapeutics tiene un patrimonio de los accionistas total de $551.8M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $622.4M y $70.6M respectivamente.
Información clave
0%
Ratio deuda-patrimonio
US$0
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$569.15m |
| Patrimonio | US$551.84m |
| Total pasivo | US$70.60m |
| Activos totales | US$622.43m |
Actualizaciones recientes sobre salud financiera
Is Sage Therapeutics (NASDAQ:SAGE) In A Good Position To Invest In Growth?
May 21
Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation
Feb 22Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation
Oct 14We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely
Jun 15We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely
Feb 26Recent updates
CNS Drug Development: Same As It Ever Was
Nov 19Sage Therapeutics: With Dalzanemdor As The Last Lifeline, Not Much Hope Left
Oct 07Why Investors Shouldn't Be Surprised By Sage Therapeutics, Inc.'s (NASDAQ:SAGE) 25% Share Price Plunge
Aug 30Sage Therapeutics: Tremors Of Trouble, But PPD Progress (Rating Downgrade)
Jul 25Revenues Working Against Sage Therapeutics, Inc.'s (NASDAQ:SAGE) Share Price
Jul 13Sage Therapeutics Stock: Remains A Hold On Upcoming Essential Tremor Treatment Data
May 30Is Sage Therapeutics (NASDAQ:SAGE) In A Good Position To Invest In Growth?
May 21Analysts Have Just Cut Their Sage Therapeutics, Inc. (NASDAQ:SAGE) Revenue Estimates By 50%
Feb 22Calculating The Fair Value Of Sage Therapeutics, Inc. (NASDAQ:SAGE)
Feb 15Sizing Up Sage Therapeutics
Jan 22Things Look Grim For Sage Therapeutics, Inc. (NASDAQ:SAGE) After Today's Downgrade
Aug 09Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation
Feb 22An Intrinsic Calculation For Sage Therapeutics, Inc. (NASDAQ:SAGE) Suggests It's 45% Undervalued
Nov 12Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation
Oct 14Sage Therapeutics GAAP EPS of -$2.13 beats by $0.02, revenue of $1.5M misses by $0.27M
Aug 02We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely
Jun 15Sage Therapeutics: Well-Funded But Uninspiring Data
Mar 24We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely
Feb 26Sage Therapeutics: Biogen's Backing May See It Through
Jan 04What You Need To Know About The Sage Therapeutics, Inc. (NASDAQ:SAGE) Analyst Downgrade Today
Aug 05Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($605.0M) de SAGE superan a sus pasivos a corto plazo ($60.4M).
Pasivo a largo plazo: Los activos a corto plazo de SAGE ($605.0M) superan a sus pasivos a largo plazo ($10.2M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: SAGE está libre de deudas.
Reducción de la deuda: SAGE no ha tenido ninguna deuda en los últimos 5 años.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: SAGE tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.
Pronóstico de cash runway: Datos insuficientes para determinar si SAGE tiene suficiente cash runway en caso de que su flujo de caja libre siga creciendo o disminuyendo basado en tasas históricas.